Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 8/20 | 0.65 |
| ▸ | NT5E | P21589 | 3/20 | 0.65 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21030881 | 0.92 | POLB (0.73) | ENPP1NT5EPLCG1POLBP2RX1 | |
| SCHEMBL285262 | 0.90 | P2RY1 (0.62) | ENPP1POLBP2RY11 | |
| SCHEMBL18837728 | 0.90 | P2RY1 (0.62) | ENPP1POLBP2RY11 | |
| SCHEMBL20959779 | 0.90 | P2RY1 (0.62) | ENPP1POLBP2RY11 | |
| SCHEMBL20225019 | 0.90 | P2RY1 (0.62) | ENPP1POLBP2RY11 | |
| SCHEMBL20225051 | 0.90 | P2RY1 (0.62) | ENPP1POLBP2RY11 | |
| SCHEMBL19145744 | 0.89 | POLB (0.54) | ENPP1NT5EPLCG1POLBP2RX1 | |
| SCHEMBL21251592 | 0.88 | BCHE (0.53) | ENPP1NT5EPLCG1POLBP2RX1 | |
| SCHEMBL21636992 | 0.88 | POLB (0.53) | ENPP1NT5EPLCG1POLBP2RX1 | |
| SCHEMBL22352087 | 0.88 | POLB (0.53) | ENPP1NT5EPLCG1POLBP2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149051-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149051-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ENPP1 481/4885NT5E 3892/4885PLCG1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.